Ivermectin to Treat Cancer

Evidence Review created on 04/22/2026 using AI4L / Opus 4.7

Also known as: Stromectol, Mectizan, Soolantra, Sklice, IVM, 22,23-dihydroavermectin B1

Motivation

Ivermectin is an antiparasitic drug derived from a soil-bacterium metabolite that has been used since the mid-1980s to treat river blindness, threadworm, scabies, and other parasitic conditions in more than three billion human courses. Its discoverers shared the 2015 Nobel Prize in Physiology or Medicine, and the drug is on the World Health Organization List of Essential Medicines with a well-characterized safety record at approved doses.

Over the past two decades, laboratory and animal work has shown that ivermectin can interfere with core growth-signalling pathways that cancer cells rely on. After high-profile podcast claims of cancer remission and a surge of off-label use, research institutions have begun funding prospective trials, and policymakers in several jurisdictions have moved to expand access.

This review examines what is known and what remains unknown about ivermectin as an anticancer agent: the mechanistic case, preclinical evidence, the small but growing human dataset, the dose-translation problem, interaction risks, and the regulatory and conflict-of-interest context shaping how the evidence is being produced and interpreted.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Ivermectin

A general reference covering ivermectin’s discovery, antiparasitic mechanism (glutamate-gated chloride channels), human approvals, dosing, and safety profile; useful primarily for background and pharmacology rather than for oncology-specific data, which it treats only briefly.

Examine

No dedicated Examine.com article for ivermectin was found. Examine.com does not typically cover prescription medications in its supplement database, which is consistent with the absence of a dedicated page for ivermectin.

ConsumerLab

No dedicated ConsumerLab article for ivermectin as a cancer therapy was found. ConsumerLab does not typically cover prescription medications with product reviews, which is consistent with the absence of a dedicated page. ConsumerLab has published two clinical updates on ivermectin (2021), both focused on COVID-19 and recommending against use outside clinical trials.

Systematic Reviews

This section lists systematic reviews that aggregate the preclinical and early-clinical evidence for ivermectin in oncology. No oncology-focused meta-analyses of human outcomes exist as of the creation date.

Ivermectin, a potential anticancer drug derived from an antiparasitic drug - Tang et al., 2021

A systematic review in Pharmacological Research mapping the signaling pathways through which ivermectin has been reported to inhibit cancer cell proliferation — PAK1/Akt/mTOR (a proliferation- and growth-regulating kinase cascade), Wnt/β-catenin (a stem-cell and tissue-patterning pathway), YAP1 (a Hippo-pathway growth co-activator), WNT-TCF (a Wnt-downstream transcription axis), and purinergic receptors — across breast, ovarian, leukemic, colorectal, glioma, and other models, and discussing translational prospects.

Note on systematic-review availability: A PubMed search for “ivermectin AND cancer AND (systematic review OR meta-analysis)” returned only the Tang et al. 2021 systematic review; other aggregations found in the literature (Juarez 2018, Hu 2024, Hayes 2025, Juarez 2020) are narrative or focused reviews rather than true systematic reviews or meta-analyses and therefore do not belong in this section. No oncology-focused meta-analysis of human outcomes exists as of the creation date.

Mechanism of Action

Ivermectin is a multi-target molecule: in parasites its primary action is on glutamate-gated chloride channels, but mammalian cancer cells lack these channels, and the anticancer activity operates through distinct pathways that have been individually characterized in preclinical models.

PAK1/Akt/mTOR inhibition: Ivermectin decreases P21-activated kinase 1 (PAK1, a kinase that drives proliferation and cytoskeletal changes) via ubiquitin-mediated degradation. The resulting drop in Akt phosphorylation suppresses the Akt/mTOR (mechanistic target of rapamycin, a master growth regulator) axis, producing cytostatic autophagy (cell survival-program self-eating that here halts division rather than rescuing the cell) in breast cancer models.
Mitochondrial dysfunction and reactive oxygen species (ROS): In colorectal and pancreatic cancer lines, ivermectin collapses the mitochondrial membrane potential, drives ROS (reactive oxygen species, chemically reactive oxygen-containing molecules that damage cellular components) overproduction, and triggers apoptosis (programmed cell death) via a Bax/Bcl-2/caspase-3 cascade.
Wnt/β-catenin suppression: Ivermectin inhibits Wnt-TCF signaling (a pathway central to stem-cell maintenance and epithelial-to-mesenchymal transition), reducing Wnt5a/b and LRP6 (low-density lipoprotein receptor-related protein 6, a Wnt co-receptor) expression and lowering invasiveness in endocrine-resistant breast cancer.
P-glycoprotein (P-gp) modulation: Ivermectin is both a substrate and, at higher concentrations, an inhibitor of P-gp/ABCB1, the efflux pump that exports chemotherapy drugs out of tumor cells. This underlies reported resensitization of paclitaxel-resistant non-small-cell lung cancer models and synergy with docetaxel and doxorubicin.
YAP1/Hippo pathway and integrins: Inhibition of Yes-associated protein 1 (YAP1, a Hippo-pathway transcription co-activator that drives proliferation) has been reported in gastric cancer, and allosteric integrin binding has been described as a further mode of action affecting tumor-immune cross-talk.
Cancer-stem-cell (CSC) targeting and immunomodulation: Stem-cell-enriched subpopulations show ivermectin sensitivity comparable to or greater than bulk tumor cells; separately, ivermectin can increase tumor immunogenicity and has been combined with PD-1 (programmed cell death protein 1, an immune checkpoint) blockade in ongoing trials.

Competing mechanistic readings. Proponents emphasize the breadth and convergence of these pathways. Skeptics emphasize that many in vitro findings occur at concentrations (typically 5–20 µM) that are hard to reach and sustain in human plasma at standard antiparasitic doses, and that the pleiotropic target list itself raises the risk of off-target effects rather than a clean anticancer mechanism.

Key pharmacological properties. Ivermectin is a 16-membered macrocyclic lactone, administered orally, with a terminal plasma half-life of approximately 18 hours for the parent compound and up to ~38 hours for active metabolites; peak plasma concentration (Cmax) is reached at roughly 4 hours post-dose. It is highly lipophilic with wide tissue distribution and long persistence in fat; CNS (central nervous system) penetration is normally restricted by P-gp efflux at the blood-brain barrier. Metabolism is primarily hepatic via CYP3A4 (cytochrome P450 3A4, a major drug-metabolizing enzyme), with biliary/fecal elimination.

Historical Context & Evolution

Ivermectin is a semi-synthetic derivative of avermectin B1, isolated in the 1970s from Streptomyces avermitilis at the Kitasato Institute in Japan by Satoshi Ōmura and developed at Merck by William C. Campbell. Merck (the originator manufacturer whose patent has long expired and which no longer holds a financial stake in ivermectin sales, and which has publicly opposed off-label use) is cited here for its historical role. It was approved for veterinary use in 1981 and for human use in 1987, originally as a single-dose treatment for onchocerciasis (river blindness). Merck’s donation program has since delivered more than three billion human doses, and Ōmura and Campbell shared the 2015 Nobel Prize in Physiology or Medicine.

The first suggestion of anticancer activity came from Russian work published in 2004 showing that avermectin mixtures suppressed growth of murine Ehrlich carcinoma and P388 lympholeukemia and enhanced vincristine activity at non-toxic doses (Drinyaev et al., 2004). From the late 2000s onward, mechanistic work identified specific cancer-relevant targets — PAK1 inactivation in ovarian cancer and NF2-driven tumors (Hashimoto et al., 2009), cytostatic autophagy via PAK1/Akt in breast cancer (Dou et al., 2016), YAP1 inhibition in gastric cancer (Nambara et al., 2017), and P-gp/MDR (multidrug resistance) reversal in multiple tumor types.

Public visibility changed sharply during and after the COVID-19 pandemic. Ivermectin was widely advocated for COVID-19 by a group of clinicians including Pierre Kory and the Front Line COVID-19 Critical Care Alliance (FLCCC, an advocacy and telehealth organization whose revenue and public profile are directly tied to the positions it promotes, including ivermectin prescribing); large randomized trials and Cochrane reviews subsequently concluded that it does not meaningfully reduce COVID-19 hospitalization or mortality, and regulators advised against off-label use for that indication. The resulting polarization spilled into the oncology discussion: anecdotal cancer-remission claims (notably on the Joe Rogan podcast in January 2025) prompted surges in off-label cancer use, while mainstream oncology bodies (professional societies whose member physicians derive revenue from administering, and hospital systems from billing for, the conventional chemotherapy and targeted-therapy regimens that an effective low-cost repurposed drug could displace) emphasized the absence of clinical trial evidence.

The current picture is neither “debunked” nor “established.” Preclinical signals are real and reproducible; human efficacy data in cancer are near-absent; formal clinical testing has only recently begun (e.g., NCT05318469 in triple-negative breast cancer opened in 2022, NCT07487805 “ICONIC” planned for 2026). The evolving evidence sits between strong advocacy and reflexive dismissal rather than aligning with either.

Expected Benefits

All entries below are framed for health- and longevity-oriented adults considering ivermectin as part of an investigational or adjunctive anticancer strategy, typically in addition to conventional oncology care. A dedicated search across the preclinical, mechanistic, and early-clinical literature was performed before drafting to ensure the profile is complete.

Medium 🟩 🟩

Broad Preclinical Antitumor Activity Across Multiple Cancer Lines

Ivermectin has consistently suppressed proliferation and induced cell death across a wide panel of cancer cell lines and rodent xenograft models — including breast (MCF-7, MDA-MB-231/-468), ovarian (SKOV-3), colorectal (SW480, SW1116), glioma, pancreatic, gastric, lung (A549), and hematologic cancers. Mechanisms converge on PAK1/Akt/mTOR blockade, mitochondrial dysfunction with ROS overproduction, and Wnt/β-catenin suppression. The breadth and reproducibility of the in vivo tumor-shrinkage signal in mice is the strongest feature of the case.

Magnitude: Tumor-size reductions of roughly 40–80% vs. vehicle control in multiple murine xenograft models; IC50 (half-maximal inhibitory concentration, the drug level that suppresses 50% of cell growth) values in the 1–20 µM range across 28 cancer cell lines.

Synergy with Established Chemotherapy Agents

In preclinical systems, ivermectin shows additive or synergistic effects with several standard oncology drugs, including docetaxel, cyclophosphamide, tamoxifen, paclitaxel, gemcitabine, and cisplatin. In paclitaxel-resistant non-small-cell lung cancer, ivermectin restores sensitivity by suppressing P-gp over-expression via the EGFR (epidermal growth factor receptor, a membrane receptor driving proliferation) / ERK (extracellular signal-regulated kinase, a kinase relaying growth signals) / Akt (a kinase controlling survival and metabolism) / NF-κB (nuclear factor kappa B, a transcription factor driving inflammation and survival genes) pathway.

Magnitude: Combination index values < 1 across multiple pairings; gemcitabine-ivermectin reduced pancreatic tumor xenograft volume by a further ~30–50% vs. gemcitabine alone.

Low 🟩

Activity Against Cancer Stem-Cell-Enriched Populations

Cancer stem cells (CSCs) — a subpopulation implicated in recurrence and chemoresistance — have shown sensitivity to ivermectin comparable to or greater than bulk tumor cells in several models, with reductions in colony-formation capacity and sphere formation. If this translates, the mechanistic rationale for reducing late recurrence is plausible, but no human data confirm a CSC-specific benefit.

Magnitude: ~50–70% reductions in colony-formation capacity and mammosphere number at 5 µM across several breast-cancer stem-cell models.

Reversal of Chemotherapy Multidrug Resistance via P-gp Inhibition

Ivermectin can both compete for and downregulate P-glycoprotein (ABCB1/MDR1), the efflux pump responsible for a large share of acquired multidrug resistance. Preclinical data show reversal of paclitaxel resistance in lung cancer and doxorubicin resistance in several other models. This is one of the more clinically plausible near-term use cases, though no human trial has yet reported resistance-reversal data.

Magnitude: Intracellular paclitaxel concentrations roughly 2–3× higher in resistant cells with co-administered ivermectin; resensitization of previously PTX-resistant A549 cells to control sensitivity levels.

Early Human Safety Signal in Immune-Checkpoint Combination

In the ongoing NCT05318469 phase I/II study of ivermectin plus balstilimab or pembrolizumab in metastatic triple-negative breast cancer, interim reporting on the first nine patients described no treatment-related serious adverse events. This is a safety, not efficacy, signal but is the first prospective human data in oncology.

Magnitude: 0 of 9 patients with treatment-related serious adverse events in interim report; efficacy outcomes not yet mature.

Speculative 🟨

Reduction of Late Recurrence

Based on the preclinical cancer-stem-cell signal and the long tissue half-life of ivermectin in fat stores, some clinicians propose low-dose maintenance dosing to reduce late recurrence after conventional treatment. Basis is mechanistic and anecdotal only; no controlled human data exist on recurrence rates.

Immune-Checkpoint Inhibitor Enhancement

Mechanistic work describing ivermectin-induced immunogenic cell death, P2X4/P2X7 purinergic activation, and tumor-microenvironment remodeling supports the hypothesis that ivermectin could potentiate PD-1/PD-L1 checkpoint inhibitors. The prospective ICONIC trial (NCT07487805) is designed to test this; until it reports, the claim remains speculative rather than demonstrated.

Activity Against Aggressive (“Turbo”) Cancers

High-dose ivermectin protocols have been proposed by Dr. William Makis and similar clinicians specifically for aggressive post-2021 cancer presentations. The clinical claim is based on selected case reports rather than controlled data, and independent verification is absent; the benefit category is listed only to accurately represent what is being claimed in the off-label community, not to endorse it.

Benefit-Modifying Factors

ABCB1/MDR1 variants: ABCB1 (also known as MDR1, the gene encoding P-glycoprotein, the efflux pump that limits drug entry to the brain and many tissues) governs whether ivermectin reaches the central nervous system; it likely also influences intratumoral drug accumulation. Individuals carrying loss-of-function ABCB1 variants may show higher tissue exposure — a double-edged sword that may increase antitumor effect and toxicity.
CYP3A4 activity: Because ivermectin is cleared primarily via CYP3A4, inter-individual differences in CYP3A4 activity (genetic, hepatic, and diet-driven) materially affect plasma concentrations and therefore the chance of reaching antitumor-relevant exposures.
Tumor type and pathway dependence: Preclinical sensitivity clusters in cancers driven by PAK1, Akt/mTOR, Wnt/β-catenin, or YAP1 signaling — including breast (especially triple-negative and endocrine-resistant), ovarian, glioma, gastric, pancreatic, and some leukemias/lymphomas. Prostate (DU145) and some other lines have shown relative resistance.
Baseline biomarker levels: Baseline tumor-specific markers (e.g., CA 15-3, CA 19-9, CEA, PSA, LDH) define the reference against which any response is judged; low baseline vitamin D, elevated CRP (C-reactive protein, a general inflammation marker), and other pre-treatment inflammation/immune markers may influence both underlying tumor trajectory and the likelihood of observing an ivermectin-attributable signal.
Sex-based differences: No sex-specific efficacy differences have been established in humans. Preclinical data skew toward female-predominant cancers (breast, ovarian), which biases what is reported.
Pre-existing conditions: Patients with hepatic impairment (altered CYP3A4 clearance), impaired blood-brain-barrier integrity, high parasite burden (especially Loa loa), or advanced frailty are more likely to experience exposure extremes at either end.
Age: Older adults typically have reduced hepatic clearance and more polypharmacy, both of which raise the probability of CYP3A4-mediated drug interactions and of reaching higher plasma concentrations than intended.
Body fat and dosing: Ivermectin is highly lipophilic and partitions into fat. Weight-based dosing (mg/kg) is standard; using lean body weight vs. total body weight can alter exposure substantially in higher-BMI (body mass index) patients.

Potential Risks & Side Effects

Dedicated review of prescribing information (Stromectol label), drugs.com, and published pharmacovigilance data was performed before drafting. The risk profile below reflects both the approved antiparasitic dose range and the substantially higher off-label cancer-protocol doses being used in practice.

High 🟥 🟥 🟥

Neurotoxicity at High Doses or in P-glycoprotein-Impaired States

Ivermectin’s safety depends on P-gp efflux keeping the drug out of the brain. At antiparasitic doses in healthy adults, CNS effects are limited to dizziness, headache, and mild somnolence. At substantially higher doses — or when P-gp is impaired (rare ABCB1 loss-of-function variants, co-administration of strong P-gp inhibitors, or after blood-brain-barrier disruption) — accumulation in the CNS can produce confusion, ataxia, tremor, seizures, encephalopathy, and coma. Severe cases have been reported in humans.

Magnitude: Incidence rare at approved doses (<1%); case reports of severe neurotoxicity with off-label high-dose regimens, including at least one patient on regorafenib with likely CYP3A4-mediated interaction.

Drug-Drug Interaction Toxicity via CYP3A4 and P-gp

Ivermectin is a CYP3A4 substrate and a P-gp substrate/inhibitor. Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, grapefruit juice) and P-gp inhibitors (cyclosporine, verapamil) can raise plasma and brain exposure and produce clinically meaningful toxicity. This is the dominant safety hazard when ivermectin is added to complex oncology regimens.

Magnitude: CYP3A4 inhibitors can raise ivermectin AUC (area under the plasma-concentration curve, a measure of total drug exposure over time) several-fold; clinically important neurotoxicity has been reported at standard ivermectin doses when combined with tyrosine kinase inhibitors (a class of targeted cancer drugs that block signaling enzymes driving tumor growth) metabolized by CYP3A4.

Medium 🟥 🟥

Hepatotoxicity

Elevated transaminases and rare cases of hepatitis have been reported in post-marketing data and in patients on high-dose protocols. Generally reversible with discontinuation, but more likely at the elevated mg/kg daily dosing used in off-label cancer protocols than at single-dose antiparasitic use.

Magnitude: Transaminase elevations reported in roughly 1–3% of high-dose users; severe hepatitis rare.

Gastrointestinal Effects

Nausea, diarrhea, abdominal pain, and loss of appetite are common, especially at higher doses and when ivermectin is combined with other antiparasitic or antineoplastic agents.

Magnitude: GI (gastrointestinal) adverse events reported in ~5–15% of users at standard doses; higher at cancer-protocol doses.

Mazzotti-like Inflammatory Reaction in Patients with Undiagnosed Parasitic Infection

A Mazzotti reaction is a systemic inflammatory response (fever, rash, swollen lymph nodes, and sometimes encephalopathy) triggered when ivermectin rapidly kills a large number of microfilarial parasites. In individuals with high parasite burden (particularly Loa loa), rapid parasite death after ivermectin exposure can precipitate a severe inflammatory reaction including encephalopathy. Less relevant in non-endemic populations, but important to rule out before starting high-dose regimens, especially in patients with exposure to endemic regions.

Magnitude: Rare in non-endemic settings; severe cases documented in endemic African populations with high microfilarial loads.

Low 🟥

Cutaneous Reactions

Rash, pruritus, and, rarely, Stevens-Johnson syndrome have been reported. Usually mild and self-limiting at standard doses.

Magnitude: Rash in roughly 1–3% of patients; severe cutaneous reactions rare.

Microbiome Disruption

Ivermectin has antibiotic-like activity against certain gut flora. Because gut-microbiome composition modulates immune-checkpoint-inhibitor response, chronic ivermectin exposure may blunt immunotherapy efficacy. This concern is a primary reason for the ICONIC trial’s prospective-microbiome assessment.

Magnitude: Not quantified in available studies.

Orthostatic Hypotension and Tachycardia

Orthostatic hypotension (a drop in blood pressure on standing, producing dizziness or fainting) and tachycardia (an abnormally fast heart rate) have both been reported. Uncommon, dose-dependent, and typically self-limiting.

Magnitude: Reported in <1% of users at approved doses.

Speculative 🟨

Long-Term Off-Target Effects at Chronic High Doses

The cancer-protocol dosing being used off-label (1–2 mg/kg daily for months) is well outside the population on which ivermectin’s long-term safety record was established (typically single or short-course dosing). Chronic cumulative effects are not characterized; concerns include long-term hepatic, renal, and neurologic accumulation. Basis is mechanistic and pharmacokinetic, not from controlled trials.

Tumor-Promoting Interactions in Specific Contexts

Isolated reports (e.g., nonprotective autophagy in lung adenocarcinoma that promoted cell survival under some conditions) raise the theoretical concern that ivermectin could be counterproductive in certain tumor biologies. No human evidence confirms this, and the dominant signal remains antitumor.

Risk-Modifying Factors

ABCB1/MDR1 polymorphisms: Rare loss-of-function variants substantially raise CNS exposure and neurotoxicity risk. Clinical genetic testing is not routine but may be considered before chronic high-dose use.
CYP3A4 activity and inducers/inhibitors: Poor metabolizers and those taking CYP3A4 inhibitors face higher systemic exposure; CYP3A4 inducers (rifampin, St. John’s wort, carbamazepine) can lower exposure and diminish any therapeutic effect.
Baseline hepatic and renal function: Impaired hepatic function slows clearance and raises accumulation risk over chronic dosing; serial liver function test (LFT) monitoring is advisable under off-label protocols.
Sex: No consistent sex-based difference in toxicity has been established in humans.
Pre-existing neurological disease, blood-brain-barrier compromise, CNS metastases, or recent head trauma: Raise the probability of CNS drug accumulation and neurotoxicity.
Age: Older adults (reduced hepatic clearance, polypharmacy) and very young children (developing blood-brain barrier) are at higher risk. The target audience of this review is adults, but older adults at the upper end of that range warrant greater vigilance.
Parasitic co-infection status: High Loa loa burden is an absolute red flag; screening is indicated in patients with prior exposure to endemic regions.
Concurrent immunotherapy: Microbiome-mediated effects raise a theoretical concern for blunted checkpoint-inhibitor response.

Key Interactions & Contraindications

Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin, grapefruit juice): severity — caution/avoid; consequence — elevated ivermectin plasma and brain concentrations with potential neurotoxicity. Mitigation: avoid co-administration or reduce ivermectin dose and monitor; separate grapefruit juice by at least several hours is inadequate — avoid.
CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John’s wort): severity — caution; consequence — reduced ivermectin exposure and likely reduced efficacy. Mitigation: avoid combinations where ivermectin efficacy is the clinical goal.
P-gp inhibitors (cyclosporine, verapamil, amiodarone, quinidine): severity — caution; consequence — raised CNS penetration and neurotoxicity risk. Mitigation: avoid or monitor neurologically; consider lower ivermectin dose.
Tyrosine kinase inhibitors (regorafenib, imatinib, sunitinib): severity — caution; consequence — reported neurotoxicity in at least one case report with regorafenib plus ivermectin via pharmacokinetic interaction. Mitigation: avoid combination or use only with careful monitoring.
Warfarin: severity — monitor; consequence — reports of prolonged prothrombin time. Mitigation: monitor INR (international normalized ratio, a measure of blood clotting time).
Other antiparasitics (fenbendazole, mebendazole, albendazole): severity — caution; consequence — additive GI and hepatic effects, especially in combination cancer protocols using all three. Mitigation: monitor LFTs and CBC (complete blood count).
Benzodiazepines, barbiturates, and valproate: severity — caution; consequence — potentiation of GABAergic CNS depression at high ivermectin doses. Mitigation: avoid high-dose overlap.
High-dose curcumin and similar CYP3A4-modulating supplements: severity — caution; consequence — altered ivermectin exposure; relevant because curcumin is common in off-label cancer protocols. Mitigation: separate dosing windows and monitor.
Populations to avoid or use with extreme caution: patients with known ABCB1 loss-of-function, high-grade hepatic impairment (Child-Pugh Class C), current CNS metastases or active seizure disorder, patients on concurrent strong CYP3A4 inhibitors that cannot be stopped, pregnant or breastfeeding women (pregnancy category C; limited data), children under 15 kg body weight, and patients with recent (within 90 days) diagnosed loiasis or residence in Loa loa endemic areas without prior microfilarial assessment.

Risk Mitigation Strategies

Pre-treatment CYP3A4 and P-gp interaction audit: review every medication and supplement for CYP3A4 and P-gp effects before initiating; prevents the dominant drug-interaction neurotoxicity risk. Document interactions and agree on substitutions or dose adjustments.
Baseline and serial laboratory monitoring: baseline comprehensive metabolic panel, liver function tests (ALT, AST, ALP, bilirubin), complete blood count, and renal function; repeat at 2 weeks, 4 weeks, then monthly under high-dose cancer-protocol use, prevents undetected hepatotoxicity and cytopenias.
Loa loa screening before high-dose regimens in at-risk individuals: blood smear or serology for patients with prior residence or travel to Central or West Africa; prevents potentially fatal Mazzotti-type encephalopathy.
Start-low, go-slow dose escalation: begin at a standard antiparasitic dose (e.g., 0.2 mg/kg) and escalate over 2–4 weeks under clinician supervision if higher protocol doses are planned; prevents acute neurotoxicity and allows for tolerability assessment.
Neurological self-monitoring and stopping rules: patients and caregivers to watch for confusion, unsteady gait, tremor, visual changes, or excessive somnolence and discontinue immediately while contacting the prescriber; mitigates irreversible CNS injury.
Time-separation from known substrate drugs: when a substrate cannot be avoided, administer ivermectin and the interacting drug at different times of day (minimum 4–6 hours apart), recognizing that time separation alone does not eliminate interaction for metabolized drugs.
Microbiome preservation during immunotherapy combinations: minimize concurrent non-ivermectin antibiotics and avoid unnecessary antiparasitic cycling during checkpoint-inhibitor treatment; mitigates the theoretical immunotherapy-blunting effect of microbiome disruption.
Source verification: use pharmacy-dispensed human-grade ivermectin (Stromectol or authenticated generics) rather than veterinary formulations; prevents dosing errors and contamination.

Therapeutic Protocol

There is no established, evidence-based therapeutic protocol for ivermectin in cancer. Several approaches circulate in clinical and integrative practice.

Conventional / trial-based approach (NCT05318469): ivermectin is given in combination with an anti-PD-1 antibody (balstilimab or pembrolizumab) in patients with metastatic triple-negative breast cancer. Ivermectin dosing follows a dose-escalation design starting at clinically characterized human doses. The planned ICONIC trial (NCT07487805) will compare intermediate-dose and high-dose ivermectin with immune-checkpoint inhibitor therapy in solid tumors. This is the approach with the highest likelihood of generating defensible human efficacy data.
Integrative / off-label clinician protocols (Pierre Kory, William Makis, FLCCC — note that FLCCC’s revenue and public profile are directly tied to the positions it promotes, including ivermectin prescribing): chronic oral dosing calibrated to cancer severity. Representative dose tiers frequently reported include: low-grade cancers, remission maintenance, or prevention: 0.5 mg/kg, three times weekly; intermediate-grade cancers: 1 mg/kg three times weekly, or 0.5–1 mg/kg daily; high-grade or aggressive cancers: 1–2 mg/kg daily, escalating in some protocols to 2.5 mg/kg/day. These tiers are typically combined with fenbendazole, vitamin D3 plus K2, curcumin, and other adjuncts. They are not validated in controlled trials, dosing substantially exceeds antiparasitic labeling, and clinician oversight (with monitoring per Risk Mitigation Strategies) is essential.
Time of day: administration with a fat-containing meal increases bioavailability roughly 2.5-fold relative to fasted dosing; most protocols recommend taking with food.
Half-life and dosing frequency: the parent compound’s plasma half-life (~18 h) and longer metabolite half-lives (~38 h) support once-daily dosing; split dosing is not standard and has not been shown to improve efficacy.
Single vs. split dose: once-daily administration is standard in all current protocols.
Genetic polymorphisms: ABCB1 and CYP3A4 variants influence both efficacy and toxicity; pharmacogenetic testing is not routine but may refine decisions in high-dose contexts. Unrelated lifestyle-genetics markers such as APOE4 (a lipoprotein variant associated with cardiovascular and neurodegenerative risk), MTHFR (a folate-metabolism enzyme gene whose variants affect methylation), and COMT (an enzyme gene that degrades catecholamines) do not directly affect ivermectin pharmacology.
Sex-based differences: no robust sex-based dose recommendations exist; preclinical work has been performed on mixed models.
Age considerations: older adults warrant lower starting doses given reduced hepatic clearance and higher interaction burden.
Baseline biomarkers: baseline tumor-specific markers (CA 15-3, CA 19-9, CEA, PSA, LDH, where relevant), hepatic and renal function, and CBC are essential for protocol interpretation.
Pre-existing conditions: hepatic impairment, CNS disease, concurrent CYP3A4-interacting medications, and prior checkpoint-inhibitor treatment should all inform protocol choice.

Discontinuation & Cycling

The question of duration is unresolved in the absence of controlled data. Trial protocols typically dose for defined treatment windows aligned with the companion regimen (e.g., checkpoint-inhibitor cycles). Off-label cancer protocols vary widely, from time-limited intensive phases of 3–6 months to indefinite low-dose maintenance.

Withdrawal effects: no pharmacological withdrawal syndrome has been described; abrupt discontinuation is not associated with rebound symptoms.
Tapering-off protocol: no formal taper is required pharmacologically; some clinicians taper doses when transitioning from an intensive phase to maintenance simply to allow for tolerability assessment.
Cycling: some integrative protocols use 5-days-on / 2-days-off or 3-weeks-on / 1-week-off cycling, motivated by microbiome recovery and liver rest rather than by efficacy data. No evidence supports or refutes cycling for efficacy preservation.

Sourcing and Quality

Human-grade prescription formulations: Stromectol (US), Mectizan (donation program), Ivexterm (Latin America), and authenticated generics are the preferred sources. These have consistent tablet strengths (typically 3 mg, 6 mg, 12 mg) and documented GMP (Good Manufacturing Practice) manufacturing.
Compounding pharmacies: some US compounding pharmacies prepare higher-strength tablets or liquid formulations for off-label use; verify state licensure, third-party testing, and batch certificates of analysis.
Avoid veterinary formulations: horse pastes and livestock injectables are not formulated for human pharmacokinetics and carry excipient and dosing risks; a spike in veterinary-formulation exposures was reported during and after the pandemic.
Third-party testing: request certificates of analysis confirming active content and absence of heavy-metal or microbial contamination, particularly for compounded or imported products.
Storage: store at controlled room temperature away from direct light; lipophilic degradation can occur with prolonged heat exposure.

Practical Considerations

Time to effect: there are no validated clinical endpoints for ivermectin alone in cancer. In reported off-label series, clinicians typically reassess at 6–12 weeks using tumor markers and imaging; antiparasitic doses reach steady state within a few days.
Common pitfalls: unsupervised dose escalation without lab monitoring, use of veterinary formulations, overlooked CYP3A4/P-gp interactions, abandoning proven standard-of-care therapy in favor of ivermectin alone, and reliance on aggregated case-series claims rather than systematic outcome data.
Regulatory status: ivermectin is FDA-approved for strongyloidiasis and onchocerciasis (oral) and for rosacea and pediculosis (topical). All oncology use is off-label; several US states have passed legislation expanding over-the-counter or pharmacist-dispensed access in 2024–2026, but this does not constitute FDA oncology approval.
Cost and accessibility: human-grade generic ivermectin is inexpensive (on the order of USD 30–80/month at typical antiparasitic doses). Higher off-label protocol doses raise costs proportionally; insurance coverage for off-label oncology use is generally absent.

Interaction with Foundational Habits

Sleep: CNS effects including somnolence and, rarely, sleep disturbance have been reported. Most users experience no meaningful change; effects are dose-dependent and more likely at high protocol doses.
Nutrition: absorption is roughly 2.5× higher when taken with food, particularly fat-containing meals; this is a potentiating interaction. Grapefruit juice and grapefruit products must be avoided (CYP3A4 inhibition). A ketogenic diet (common in integrative cancer protocols) changes fat intake patterns and may raise Cmax.
Exercise: no direct interaction with training adaptations has been characterized. Theoretical concerns about mitochondrial ROS overlap with exercise-induced ROS are not supported by clinical data. Impact on cardiovascular exercise capacity at antiparasitic doses appears negligible.
Stress management: no direct cortisol or HPA-axis (hypothalamic-pituitary-adrenal axis, the body’s central stress-hormone system) effect is established. Indirect interactions may occur via sleep and GI effects.

Monitoring Protocol & Defining Success

Baseline laboratory evaluation should be completed before initiation, with structured follow-up tied to dose intensity. The table below reflects functional-medicine-oriented targets for adults on off-label cancer protocols; conventional reference ranges differ in some cases and are noted.

Ongoing monitoring cadence: at 2 weeks, 4 weeks, 8 weeks, then every 3 months under chronic high-dose protocols, with additional checks if new symptoms emerge or interacting medications are added.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
ALT	< 25 U/L (male), < 20 U/L (female)	Detects hepatic injury early under chronic dosing	ALT = alanine aminotransferase. Conventional cutoff ~ 40 U/L; rise of >2× baseline warrants review
AST	< 25 U/L	Hepatic injury; paired with ALT	AST = aspartate aminotransferase. Conventional upper limit ~ 40 U/L
ALP	40–90 U/L	Cholestatic injury under chronic high-dose use	ALP = alkaline phosphatase. Elevations often isolated and benign but should trigger review
Total bilirubin	< 1.0 mg/dL	Confirms hepatic excretory function	Elevation with transaminases suggests drug-induced liver injury
CBC with differential	WBC 4.5–7.5 K/µL; Platelets 200–400 K/µL	Detects cytopenias especially in combination regimens	WBC = white blood cell count. Check before/after dose escalation
Creatinine / eGFR	eGFR > 80 mL/min/1.73 m²	Renal clearance is minor but baseline is essential	eGFR = estimated glomerular filtration rate, a measure of kidney filtration capacity. Conventional cutoff eGFR > 60
Tumor-specific markers (CA 15-3, CA 19-9, CEA, PSA, LDH)	Stable or falling from baseline	Surrogate response indicator	Specific to tumor type; not a substitute for imaging
25-hydroxy vitamin D	50–80 ng/mL	Commonly co-supplemented; modulates immune response	Functional range wider than conventional reference
CRP (C-reactive protein)	< 1.0 mg/L	Systemic inflammation tracking	High-sensitivity assay preferred
Fasting glucose / HbA1c	Glucose 70–90 mg/dL; HbA1c < 5.4%	Metabolic context for overall treatment	HbA1c = hemoglobin A1c, a marker of average blood glucose over the prior 2–3 months. Non-fasting glucose values less informative

Qualitative markers to track:

Energy and fatigue (daily rating)
Pain trajectory (0–10 scale at consistent times)
Cognitive clarity (self-rating, reviewed with caregiver)
Balance and coordination (weekly heel-to-toe walk)
GI tolerance (stool pattern, appetite, weight)
Sleep quality and duration

Success at the functional level is defined by the intersection of objective marker stability or improvement, imaging stability or response, absence of emerging toxicity, and preserved quality of life.

Emerging Research

NCT05318469 — Ivermectin with balstilimab or pembrolizumab in metastatic triple-negative breast cancer: Phase I/II, enrollment 34, recruiting since 2023 (PI: Yuan Yuan). Primary endpoints include tolerability, objective response rate, progression-free survival. Interim safety data (first 9 patients) reported no treatment-related serious adverse events. NCT05318469
NCT07487805 — ICONIC (Ivermectin Combined With Immune Checkpoint Inhibition in Cancer): Phase II, enrollment 80, University of Florida, planned start 2026. Intermediate-dose vs. high-dose ivermectin with checkpoint inhibitors; prospective microbiome and pharmacodynamic assessment. NCT07487805
NCT02366884 — Atavistic Chemotherapy (Dr. Frank Arguello Cancer Clinic): Phase II, status Unknown; uses combinations of antibacterial, antifungal, and antiprotozoal drugs including ivermectin in advanced cancers. Of weaker evidentiary value given status uncertainty and design. NCT02366884
Translational pharmacology: work by Juarez et al., 2020 quantified antitumor activity at clinically feasible ivermectin concentrations and is the reference document for dose-translation debates; future studies will need to confirm whether the 5 µM concentrations used in vitro translate to tissue exposures achievable under human dosing.
Microbiome and immune-checkpoint-inhibitor interaction: ICONIC’s prospective microbiome analysis will generate the first controlled data on whether ivermectin’s antibacterial activity blunts checkpoint-inhibitor response, a genuine concern given the established role of the gut microbiome in immunotherapy outcomes.
Resistance reversal: findings from Hayashi et al., 2024 on ivermectin reversing paclitaxel resistance via P-gp downregulation in non-small-cell lung cancer could motivate targeted resistance-reversal trials if replicated in xenograft models with clinically relevant dosing.
Counter-signals: Li et al., 2024 reported that ivermectin-induced autophagy was nonprotective in lung adenocarcinoma but also described contexts where autophagy supported survival — a reminder that mechanism is context-dependent and that future trials should stratify by tumor biology.

Conclusion

Ivermectin is a well-characterized antiparasitic drug with a large preclinical body of work pointing to several cancer-relevant mechanisms: interference with core growth-signalling pathways, damage to cancer-cell energy production, suppression of a pathway linked to stem-cell survival, and blockade of a drug-expelling pump that often drives chemotherapy resistance. In animal tumor models and across many cell lines, it slows growth and adds to or synergizes with established chemotherapy and immune-checkpoint drugs.

The human evidence is another story. As of early 2026, no completed randomized trial has tested ivermectin as a cancer therapy; one early-phase trial is underway and a mid-phase combination trial is planned. Off-label use is widespread and built on anecdote, case series, and mechanistic extrapolation — not on controlled outcomes.

For a risk-aware adult, the balance includes a lengthy antiparasitic safety record at approved doses, substantial uncertainty at the higher doses used in cancer protocols, and real interaction hazards with drugs sharing the same liver-metabolism and tissue-transport routes. The evidence base is also shaped by unusual forces: oncology associations, pharmaceutical priorities, patent economics, pandemic-era polarization, and a structural asymmetry in which ivermectin’s low cost may give institutional payers an incentive to favor it while removing the commercial pull that funds large confirmatory trials. The mechanistic case is serious; current human data do not yet support confident efficacy claims.

Top - Benefits - Risks - Protocol

Ivermectin to Treat Cancer

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

Medium 🟩 🟩

Broad Preclinical Antitumor Activity Across Multiple Cancer Lines

Synergy with Established Chemotherapy Agents

Low 🟩

Activity Against Cancer Stem-Cell-Enriched Populations

Reversal of Chemotherapy Multidrug Resistance via P-gp Inhibition

Early Human Safety Signal in Immune-Checkpoint Combination

Speculative 🟨

Reduction of Late Recurrence

Immune-Checkpoint Inhibitor Enhancement

Activity Against Aggressive (“Turbo”) Cancers

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Neurotoxicity at High Doses or in P-glycoprotein-Impaired States

Drug-Drug Interaction Toxicity via CYP3A4 and P-gp

Medium 🟥 🟥

Hepatotoxicity

Gastrointestinal Effects

Mazzotti-like Inflammatory Reaction in Patients with Undiagnosed Parasitic Infection

Low 🟥

Cutaneous Reactions

Microbiome Disruption

Orthostatic Hypotension and Tachycardia

Speculative 🟨

Long-Term Off-Target Effects at Chronic High Doses

Tumor-Promoting Interactions in Specific Contexts

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion